GGrantIndex
← Leaderboards

Mark J Levis

Johns Hopkins University

$4,468,842
Attributed
$4,468,842
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $754.3K · FY200513
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$4,468,842 · 4

By mechanism

P50$2,095,210 · 2
R01$1,681,082 · 1
K08$692,550 · 1

Top collaborators

No co-investigators on record.

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsLeukemiaClinical ResearchChemotherapySamplingTyrosine Kinase InhibitorResistanceMutationIn VitroReceptor Protein-Tyrosine KinasesFlt3 InhibitorCytotoxicSmall MoleculeBiological ModelsBlast CellInhibitor/AntagonistPharmaceutical PreparationsFlt3 InhibitionFlt3 GeneCellsResponseChemotherapeutic AgentAnimal ModelLeukemia, Myelocytic, Acute

Grant awards (16)

Incorporating FLT3 Inhibitors into Acute Myeloid Leukemia(AML)Treatment Regimens$297,599
P50 · FY2013 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$347,806
P50 · FY2012 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$330,091
R01 · FY2012 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$387,019
P50 · FY2011 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$330,091
R01 · FY2011 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$381,038
P50 · FY2010 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2010 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$414,005
P50 · FY2009 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2009 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2008 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$267,743
P50 · FY2008 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2007 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2006 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2005 · CA
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2004 · CA
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2003 · CA